Company news

8 articles on JNJ

1. JNJOct 25, 2026Company release
   Subcutaneous RYBREVANT shows 77% overall response rate in head and neck cancer

   Johnson & Johnson said the results from the Phase 1b/2 OrigAMI-4 study support the ongoing pivotal Phase 3 OrigAMI-5 study.

2. JNJOct 24, 2026Company release
   Johnson & Johnson says perioperative apalutamide cut recurrence or death risk 62%

   The results come from a Phase 3 PROTEUS substudy of 408 patients, compared with radical prostatectomy alone.

3. JNJOct 19, 2026Company release
   Johnson & Johnson reports one-year FUZION data for TREMFYA in Crohn's with perianal fistula

   Combined fistula remission at Week 48 rose from 28% at Week 24 to 35% in the 100 mg every 8 weeks group.

4. JNJOct 12, 2026Company release
   Johnson & Johnson reports consistent TREMFYA fistula remission across Crohn's subgroups

   In the overall study population, combined fistula remission was 28% with the 100 mg every eight weeks dose and 27% with the 200 mg every four weeks dose, versus 10% with placebo at Week 24.

5. JNJOct 12, 2026Company release
   Johnson & Johnson reports three-year Tremfya data in moderately to severely active Crohn's disease

   At Week 144, 94% of patients on the 100 mg every-eight-weeks regimen achieved clinical remission, according to the company.

6. JNJOct 9, 2026Company release
   Johnson & Johnson shares two-year Phase 3 data for ICOTYDE in plaque psoriasis

   Nearly three-quarters of patients achieved clear or almost clear skin at two years, the company said.

7. JNJOct 2, 2026Company release
   Johnson & Johnson reports two-year ICOTYDE data in difficult-to-treat plaque psoriasis

   At Week 112, 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance.

8. JNJSep 29, 2026Company release
   Johnson & Johnson presents new IMAAVY data in generalized myasthenia gravis

   Two-year long-term extension data show sustained disease control, improved daily function and muscle strength, and lower corticosteroid use in anti-AChR+ adolescents.